Jupiter Neurosciences Inc Dossier
Qualitative Analysis
Business overview
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is a clinical-stage biopharmaceutical company headquartered in Jupiter, Florida. Incorporated in Delaware in January 2016, the company is dedicated to developing therapies that target neuroinflammation, central nervous system (CNS) disorders, and rare diseases. Its core scientific platform is built around JOTROL™, a patented, enhanced oral formulation of resveratrol designed to overcome the compound's historically poor bioavailability and gastrointestinal side effects. Jupiter operates a dual-path business model combining prescription drug development with a direct-to-consumer longevity product line under the Nugevia™ brand.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead therapeutic candidate JOTROL™ (a patented trans-resveratrol micellar formulation with 9-fold higher bioavailability) through the Phase 2a RESET clinical trial. The multi-center, randomized, double-blind, placebo-controlled study is enrolling 30 patients across study centers in DC, Maryland, and Virginia to evaluate safety, tolerability, and pharmacokinetics.
Expected impact: Aims to establish JOTROL™ as a disease-modifying therapy in the multi-billion-dollar Parkinson's Disease market, which currently lacks approved disease-modifying options.
Commercializing Nugevia™, a premium consumer longevity and wellness supplement line leveraging the same micellar delivery technology as JOTROL™. The product line launched with three initial SKUs (GLO, PWR, and MND) targeting pillars of healthy aging, mental wellness, and mitochondrial support.
Expected impact: Establishes a near-term, high-margin revenue stream to run in parallel with and support the long-term clinical development pipeline.
Expanding the business footprint in the Asia-Pacific region through strategic development and regulatory partnerships, including agreements with Sichuan Kelun, Tianjin Pharmaceuticals, and Dominant Treasure Health to facilitate market entry and potential out-licensing of JOTROL™.
Expected impact: Accelerates clinical development and regulatory approval pathways in high-growth Asian pharmaceutical and traditional medicine markets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Secures exclusive, perpetual United States licensing rights to ALA-002, a patented, next-generation MDMA-based therapeutic candidate. This positions Jupiter at the forefront of the regulated psychedelic medicine market following federal policy changes accelerating access to investigational therapies.
Terms: Upfront payment of $3.33 million, consisting of $1.50 million in cash and $1.83 million in JUNS common stock (subject to a 120-day lock-up), with additional development milestone payments and single-digit royalties up to a total potential consideration of $100 million.
Joint development of consumer-focused nutritional products targeting longevity, aging, and healthspan, leveraging Aquanova's proprietary micellar technology which forms the foundation of JOTROL™ and the Nugevia™ product line.
Terms: Annual license fee of $75,000 owed to Aquanova upon acceptance of product formulations, ending in the year of marketing authorization approval in a single territory.